Zai Lab Limited - American Depositary Shares (ZLAB)
ZLAB moved a median of 0.00% 30 minutes after news, and +0.06% by the close. How ZLAB actually reacts to news — the realized, point-in-time move the market made, measured across 415 labeled events over the last three years with zero look-ahead.
ZLAB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.07% | 44% | 412 |
| 30-min | 0.00% | 49% | 414 |
| 60-min | +0.09% | 54% | 414 |
| to close | +0.06% | 52% | 410 |
| Middle 50% of ZLAB reactions | -0.91% to +0.78% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 415 |
Half of all Zai Lab Limited - American Depositary Shares news events land between -0.91% and +0.78% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ZLAB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 10 | +0.17% | 50% | +0.57% |
| Rating reiterations | 37 | 0.00% | 49% | -0.16% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ZLAB ranks against every other measured name →
That’s how ZLAB usually reacts — get an email when it moves on news →Email me when ZLAB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ZLAB's baseline. Nothing else.
Recent ZLAB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Press release | Business Wire | -1.75% | -1.11% | |
| Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis | Press release | Business Wire | +1.94% | +1.54% | |
| Form 10-Q Zai Lab Ltd For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +9.61% | |
| Form 8-K Zai Lab Ltd For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +9.61% | |
| Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates | Press release | Business Wire | +0.00% | +9.61% | |
| U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) | Press release | Business Wire | -0.55% | -0.66% | |
| Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 | Press release | Business Wire | +0.14% | -0.77% | |
| Form 8-K Zai Lab Ltd For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | -1.46% | |
| Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas | Press release | Business Wire | -0.84% | -0.78% | |
| Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer | Press release | Business Wire | -0.48% | +1.03% | |
| Form 8-K Zai Lab Ltd For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +1.50% | +1.25% | |
| Zai Lab Announces Changes to Senior Leadership Team | Press release | Business Wire | +1.50% | +1.25% | |
| Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) | Press release | Business Wire | +1.19% | +1.03% | |
| Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates | Press release | Business Wire | +1.84% | -4.19% | |
| Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026 | Press release | Business Wire | -1.03% | -5.38% | |
| Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Ra Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases | Press release | Business Wire | +1.91% | +4.64% | |
| Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | Press release | Business Wire | +0.79% | +0.46% | |
| Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy | Press release | Business Wire | +0.93% | +2.26% | |
| Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) | Press release | Business Wire | -0.84% | -0.79% | |
| Form 10-K Zai Lab Ltd For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.11% | +4.73% | |
| Form 8-K Zai Lab Ltd For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | +4.73% | |
| Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates | Press release | Business Wire | +0.11% | +4.73% | |
| Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026 | Press release | Business Wire | +0.38% | +4.71% | |
| Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +0.11% | -1.00% | |
| Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors | Press release | Business Wire | +1.30% | -1.14% | |
| Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | -0.08% | -0.11% | |
| Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia | Press release | Business Wire | +1.10% | -1.30% | |
| Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis | Press release | Business Wire | +0.42% | -0.94% | |
| Zai Lab Announces Updates to China’s National Reimbursement Drug List | Press release | Business Wire | +0.42% | -0.94% | |
| Form 10-Q Zai Lab Ltd For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.65% | -0.04% | |
| Form 8-K Zai Lab Ltd For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | -0.04% | |
| Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates | Press release | Business Wire | -0.65% | -0.04% | |
| Zai Lab Announces Participation in Investor Conferences in November and December 2025 | Press release | Business Wire | +1.01% | +1.63% | |
| Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study | Press release | Business Wire | +0.65% | -5.56% | |
| Form 8-K Zai Lab Ltd For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | -0.39% | |
| Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 | Press release | Business Wire | -0.27% | -1.31% | |
| Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference | Press release | Business Wire | +0.25% | -0.92% | |
| Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong | Press release | Business Wire | +1.25% | +1.77% | |
| Zai Lab Announces Participation in Investor Conferences in September 2025 | Press release | Business Wire | -0.23% | +0.00% | |
| Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer | Press release | Business Wire | +0.68% | — | |
| Zai Lab Establishes Oncology Scientific Advisory Board | Press release | Business Wire | +0.16% | +1.26% | |
| Form 10-Q Zai Lab Ltd For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.87% | -1.16% | |
| Form 8-K Zai Lab Ltd For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -0.87% | -1.16% | |
| Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates | Press release | Business Wire | -0.87% | -1.16% | |
| Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025 | Press release | Business Wire | -1.39% | -1.13% | |
| Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer | Press release | Business Wire | -0.63% | -3.56% | |
| Form 8-K Zai Lab Ltd For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -1.43% | -3.14% | |
| Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 | Press release | Business Wire | +1.07% | -1.18% | |
| Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting | Press release | Business Wire | -0.10% | +3.97% | |
| Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting | Press release | Business Wire | -0.10% | +3.97% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ZLAB section they belong to.
Where else ZLAB is measured.
ZLAB earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BIOPHARMX CORP (BPMX) | 416 | -1.58% | 28% |
| VITAL THERAPIES (VTL) | 415 | -0.05% | 44% |
| Bausch Health Companies Inc. (BHC) | 412 | +0.06% | 50% |
| Verastem, Inc. (VSTM) | 411 | -0.09% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Zai Lab Limited - American Depositary Shares's median reaction calculated?
Every labeled ZLAB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 415 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of ZLAB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ZLAB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.